Buoyed by the forex benefit and strong underlying growth, Novo Nordisk reported another strong quarter. Q2 sales were up 8% at LC to DKK27.1bn, driven by both Diabetes and Obesity care (+8%), and Biopharmaceuticals (+10%) segments. Favourable product mix (higher-margin Victoza), productivity improvements, lower R&D expenses (due to the discontinuation of inflammatory activities) led to 15% growth in the operating profit to DKK12.5bn. Significant forex benefits catapulted reported sales gr
21 Aug 2015
Strong Q2 but pricing pressures and weak China conspicuous
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q2 but pricing pressures and weak China conspicuous
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
21 Aug 2015 -
Author:
Kamla Singh -
Pages:
3
Buoyed by the forex benefit and strong underlying growth, Novo Nordisk reported another strong quarter. Q2 sales were up 8% at LC to DKK27.1bn, driven by both Diabetes and Obesity care (+8%), and Biopharmaceuticals (+10%) segments. Favourable product mix (higher-margin Victoza), productivity improvements, lower R&D expenses (due to the discontinuation of inflammatory activities) led to 15% growth in the operating profit to DKK12.5bn. Significant forex benefits catapulted reported sales gr